- This event has passed.
WEBINAR: The way forward to making these ground-breaking treatments available and accessible to all Australians and Mind Medicine Australia’s primary mission
Wednesday April 8 @ 5:30 pm - 6:30 pmFree
Join this free, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.
This webinar will provide an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia is doing here in Australia to make these medicines available. This webinar will focus on the current mental health crisis that our country is facing, the role that Mind Medicine Australia will play in innovation in treatments, the benefits of psychedelic-assisted medicines and their clinical efficacy. We will also present an overview of the Mind Medicine Australia 4 key pillars and the strategy we will employ to introduce these medicines into the mainstream clinical treatment protocol for those suffering from chronic mental health conditions.
Date: Wednesday 8 April 2020
Time: 5:25pm for 5:30pm start – 6:00pm (incl Q&A)
The presentation WILL BEGIN AT 5:30pm.
Location: Online. A link will be emailed to you with the viewing details once you have registered.
Part 1: The drastic problem we face with current mental health statistics
- The number of people in the population experiencing a mental health condition
- The most common types of mental illnesses we aim to address
- Sectors of the population who are more prone to a chronic mental health condition
- What is the economic cost to the country due to this crisis and cost to their families
- A “more of the same approach” isn’t going to solve the problem
Part 2: Mind Medicine Australia and who we are
- Our purpose
- Who we are and our mission
- Overview of our Board of Directors, Staff and Advisory Panel
Part 3: Leveraging these breakthrough therapies
- Providing new treatments for chronic conditions
- Overview of method of administration of these medicines in a clinical environment
- Medicine safety record
Part 4 and 5: Outstanding Clinical Results
- Remarkable treatment outcomes
- How they work and improve brain function
- Treating the cause
- Involvement of major institutions and their clinical trials
- Presenting Australia’s first clinical trial
Part 6: Viewed from a historical context
- Use of these medicines throughout history
- The war on drugs
Part 7: Our strategy
- Four Key Strategic Areas
Following the presentation there will be a Q & A panel with Peter Hunt AM, Tania de Jong AM and Melissa Warner. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
More about the presenters
Peter Hunt AM
Founder & Chair of Mind Medicine Australia
As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.
Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia
Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.
Dr Simon Longstaff AO
Executive Director of The Ethics Centre and Director of Mind Medicine Australia
Dr Simon Longstaff commenced his work as the first Executive Director of The Ethics Centre in 1991. He undertook postgraduate studies in Philosophy as a Member of Magdalene College, Cambridge.
Simon is a Fellow of CPA Australia and in June 2016, was appointed an Honorary Professor at the Australian National University – based at the National Centre for Indigenous Studies. Formerly serving as the inaugural President of The Australian Association for Professional & Applied Ethics, Simon serves on a number of boards and committees across a broad spectrum of activities. He was formerly a Fellow of the World Economic Forum.
Simon’s distinguished career includes being named as one of AFR Boss’ True Leaders for the 21st century. In 2013 Dr Longstaff was made an officer of the Order of Australia (AO) for “distinguished service to the community through the promotion of ethical standards in governance and business, to improving corporate responsibility, and to philosophy.”
He is a Director of Mind Medicine Australia.
Education and Communications Officer of Mind Medicine Australia
Melissa Warner is an advocate for innovative solutions for mental health. Melissa is Education and Communications Officer at Mind Medicine Australia and Secretary of Psychedelic Research in Science and Medicine. Melissa has been recognised as a young leader by her appointment to the UK-Australian Young Leaders Forum. After graduating in Neuroscience from the University of Melbourne, Melissa travelled to leading centres of psychedelic-assisted psychotherapy, positive technology and Buddhist meditation internationally to forecast next-generation mental health treatments.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.
Please click here to make a tax-deductible donation.
Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes.
Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms.
You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar).
Breaches of these guidelines may result in not being able to participate in the event.
We thank you for support and cooperation on these matters.